EpiEndo successfully completes phase 1 study into respiratory treatment
Orally available EP395 has met all endpoints in safety and is now undergoing phase 2 planning
Read More
Tag: Respiratory
AZ and ICL link to research respiratory diseases
AstraZeneca and Imperial College London have announced plans to work together on investigating the scientific mechanisms and underlying drivers of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).
Read More
AZ and Pieris link in $2.1bn respiratory deal
AstraZeneca has hooked up with US group Pieris Pharmaceuticals to develop novel inhaled medicines for respiratory diseases in a deal potentially worth $2.1 billion.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
